Short Term Effects of Atorvastatin on Endothelial Functions and Oxidized LDL Levels in Patients with Type 2 Diabetes

被引:29
作者
Akalin, Aysen [1 ]
Temiz, Gokhan [2 ]
Akcar, Nevbahar [3 ]
Sensoy, Banu [3 ]
机构
[1] Eskisehir Osmangazi Univ, Fac Med, Dept Endocrinol, Eskisehir, Turkey
[2] Eskisehir Osmangazi Univ, Fac Med, Dept Internal Med, Eskisehir, Turkey
[3] Eskisehir Osmangazi Univ, Fac Med, Dept Radiol, Eskisehir, Turkey
关键词
Atherosclerosis; Atorvastatin; Endothelial dysfunction; Oxidized LDL; Type; 2; diabetes;
D O I
10.1507/endocrj.K07E-121
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: This study was designed in order to investigate the short term effects of atorvastatin on endothelial function and oxidized LDL (oxLDL) levels and to evaluate the association of endothelial dysfunction to oxLDL levels and inflammatory markers in type 2 diabetic patients. Material and Methods: Thirty type 2 diabetic and I I healthy Subjects with LDL levels between 100-160 mg/dl. without a history of cardiovascular event were included in the Study. Both groups were matched with respect to age, gender, body mass indices and lipid levels. Flow- mediated dilatation (endothelium dependent, FMD) and nitroglycerine-induced dilatation (endothelium independent, NID) were measured in the brachial artery using high-resolution ultrasound in all participants and carotid artery intima media thickness (IMT) were also evaluated. OxLDL levels, lipid parameters, blood glucose, C-peptide, HbA1c and inflammatory markers including C-reactive protein (CRP), Fibrinogen, erythrocyte sedimentation rate (ESR) were Studied. Type 2 diabetic patients received 10 mg. Atorvastatin for 6 weeks and FMD and NID were reevaluated and oxLDL levels and inflammatory markers remeasured. Results: Basal FMD, NID, IMT and oxLDL levels besides inflammatory markers were not significantly different between patients and controls. No correlation was found between inflammatory markers and FMD and NID. Only IMT correlated with fibrinogen levels obtained before treatment. In non-diabetics, IMT also correlated with oxLDL levels (p: 0.013). FMD and NID significantly improved after atorvastatin therapy ((7.62 +/- 7.6 vs. 12.65 +/- 7.8, p<0.001 and 18.22 +/- 9.57 vs. 21.43 +/- 9.6, p: 0.007, respectively). Atorvastatin significantly reduced oxLDL levels (57.85 +/- 10.33 vs. 44.36 +/- 6.34, p<0.001). Conclusion: Atorvastatin improves endothelial functions and reduces oxLDL levels in type 2 diabetics with average lipid levels in the short term and may have beneficial effects in the prevention of early atherosclerotic changes.
引用
收藏
页码:861 / 866
页数:6
相关论文
共 19 条
[1]   Pleiotropic effects of statins and related pharmacological experimental approaches [J].
Alegret, M. ;
Silvestre, J. S. .
METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, 2006, 28 (09) :627-656
[2]   Nitric oxide, atherosclerosis and the clinical relevance of endothelial dysfunction [J].
Anderson, TJ .
HEART FAILURE REVIEWS, 2003, 8 (01) :71-86
[3]   The effect of statin therapy on endothelial function in type 2 diabetes without manifest cardiovascular disease [J].
Beishuizen, ED ;
Tamsma, JT ;
Jukema, J ;
Van de Ree, MA ;
VAn der Vijver, JCM ;
Meinders, AE ;
Huisman, MV .
DIABETES CARE, 2005, 28 (07) :1668-1674
[4]   Approaches to prevention of cardiovascular complications and events in diabetes mellitus [J].
Coccheri, Sergio .
DRUGS, 2007, 67 (07) :997-1026
[5]   Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery - A report of the International Brachial Artery Reactivity Task Force [J].
Corretti, MC ;
Anderson, TJ ;
Benjamin, EJ ;
Celermajer, D ;
Charbonneau, F ;
Creager, MA ;
Deanfield, J ;
Drexler, H ;
Gerhard-Herman, M ;
Herrington, D ;
Vallance, P ;
Vita, J ;
Vogel, R .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 39 (02) :257-265
[6]   Two types of circulating endothelial progenitor cells in patients receiving long term therapy by HMG-CoA reductase inhibitors [J].
Deschaseaux, Frederic ;
Selmani, Zohair ;
Falcoz, Pierre-Emmanuel ;
Mersin, Nursen ;
Meneveau, Nicolas ;
Penfornis, Alfred ;
Kleinclauss, Colette ;
Chocron, Sidney ;
Etievent, Joseph-Philippe ;
Tiberghien, Pierre ;
Kantelip, Jean-Pierre ;
Davani, Siamak .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2007, 562 (1-2) :111-118
[7]   The effects of atorvastatin on endothelial function in diabetic patients and subjects at risk for type 2 diabetes [J].
Economides, PA ;
Caselli, A ;
Tiani, E ;
Khaodhiar, L ;
Horton, ES ;
Veves, A .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (02) :740-747
[8]   SIMVASTATIN INHIBITS THE OXIDATION OF LOW-DENSITY LIPOPROTEINS BY ACTIVATED HUMAN MONOCYTE-DERIVED MACROPHAGES [J].
GIROUX, LM ;
DAVIGNON, J ;
NARUSZEWICZ, M .
BIOCHIMICA ET BIOPHYSICA ACTA, 1993, 1165 (03) :335-338
[9]   Diabetes mellitus and vascular lesions [J].
Hayoz, D ;
Ziegler, T ;
Brunner, HR ;
Ruiz, J .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1998, 47 (12) :16-19
[10]   Lipid-lowering therapy with fluvastatin inhibits oxidative modification of low density lipoprotein and improves vascular endothelial function in hypercholesterolemic patients [J].
Inoue, T ;
Hayashi, M ;
Takayanagi, K ;
Morooka, S .
ATHEROSCLEROSIS, 2002, 160 (02) :369-376